Spots Global Cancer Trial Database for bkm120
Every month we try and update this database with for bkm120 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients | NCT01068483 | Breast Cancer Colon Cancer Ovarian Cancer Endometrium Can... | BKM120 | 18 Years - | Novartis | |
| Study of BKM120 in Advanced Squamous Cell Carcinoma of Head and Neck | NCT01527877 | Head Neck Cance... Head Neck Cance... | BKM120 | 20 Years - 80 Years | Yonsei University | |
| Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer | NCT01953445 | Breast Neoplasm... | paclitaxel BKM120 | 18 Years - | Washington University School of Medicine | |
| BKM120 For Triple Negative Breast Cancer | NCT01790932 | Breast Cancer | BKM120 | 18 Years - | Dana-Farber Cancer Institute | |
| Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer | NCT02404844 | Breast Cancer | BKM120 Tamoxifen | 18 Years - | University Hospital, Essen | |
| A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi | NCT01633060 | Metastatic Brea... | Fulvestrant BKM120 BKM120 matching... | 18 Years - | Novartis | |
| BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer | NCT01571024 | Advanced Solid ... Metastatic Colo... Metastatic Panc... | BKM120 mFOLFOX6 | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme | NCT01934361 | Recurrent Gliob... | buparlisib carboplatin lomustine placebo | 18 Years - | Novartis | |
| Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients | NCT01634061 | Castration-resi... | BEZ235 BKM120 BEZ235 BKM120 | 18 Years - | Novartis | |
| Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme | NCT01349660 | Glioblastoma Mu... | Bevacizumab BKM120 | 18 Years - | SCRI Development Innovations, LLC | |
| LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma | NCT02159066 | Melanoma | LGX818 MEK162 LEE011 BGJ398 BKM120 INC280 | 18 Years - | Pfizer | |
| A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab | NCT01285466 | Metastatic or L... | BEZ235 + paclit... BKM120 + paclit... BEZ235 + paclit... BKM120 + paclit... | 18 Years - | Novartis | |
| BKM120 in Advanced, Metastatic, or Recurrent Endometrial Cancers | NCT01550380 | Endometrial Can... | BKM120 | 18 Years - | University of Utah | |
| BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy | NCT01806649 | Esophageal Canc... | BKM120 | - | Prince of Songkla University | |
| Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma | NCT02049541 | Extranodal Marg... Nodal Marginal ... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenström Mac... | PI3K inhibitor ... rituximab Pharmacodynamic... Correlative stu... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Phase II, Open Label, Non-randomized, Trial of BKM120 for Metastatic or Locally Advanced Cervical Cancer | NCT01613677 | Treatment for M... | BKM120 | 18 Years - | Novartis | |
| Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme | NCT01934361 | Recurrent Gliob... | buparlisib carboplatin lomustine placebo | 18 Years - | Novartis | |
| A Trial of Irinotecan and BKM120 in Previously Treated Advanced Colorectal Cancer | NCT01304602 | Colorectal Canc... | Irinotecan BKM120 | 18 Years - | University of Kansas Medical Center | |
| Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients | NCT01068483 | Breast Cancer Colon Cancer Ovarian Cancer Endometrium Can... | BKM120 | 18 Years - | Novartis | |
| BKM120 in Metastatic Castration-resistant Prostate Cancer | NCT01385293 | Prostate Cancer Metastatic (Spr... | BKM120 | 18 Years - | Duke University | |
| Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma | NCT02049541 | Extranodal Marg... Nodal Marginal ... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenström Mac... | PI3K inhibitor ... rituximab Pharmacodynamic... Correlative stu... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma | NCT01512251 | BRAF Mutant Met... | BKM120 Combined... | 18 Years - | University of California, San Francisco | |
| NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer | NCT01816594 | HER2-positive N... | BKM120 Trastuzumab Paclitaxel BKM120 Placebo | 18 Years - | Novartis | |
| A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma | NCT02756247 | Lymphoma Mantle Cell Lym... Follicular Lymp... Diffuse Large B... | Buparlisib Ibrutinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy | NCT01806649 | Esophageal Canc... | BKM120 | - | Prince of Songkla University | |
| BKM120 in Cancers With PIK3CA Activating Mutations | NCT01501604 | Lung Cancer Breast Cancer Colorectal Canc... Cholangiocarcin... Solid Tumors | BKM120 | 18 Years - | Massachusetts General Hospital | |
| NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer | NCT01816594 | HER2-positive N... | BKM120 Trastuzumab Paclitaxel BKM120 Placebo | 18 Years - | Novartis | |
| A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer | NCT01629615 | Breast Cancer | BKM120 | 18 Years - | SOLTI Breast Cancer Research Group | |
| BKM120 in Metastatic Castration-resistant Prostate Cancer | NCT01385293 | Prostate Cancer Metastatic (Spr... | BKM120 | 18 Years - | Duke University | |
| Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy | NCT01852292 | Head and Neck S... | Buparlisib Buparlisib matc... Paclitaxel | 18 Years - | Novartis | |
| GINECO-EN102b - BKM120 as Monotherapy in the Treatment of Initial or Recurrent Metastatic Endometrial Cancer | NCT01397877 | Endometrial Can... | BKM120 | 18 Years - | ARCAGY/ GINECO GROUP | |
| Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer | NCT01300962 | Metastatic Brea... | BMK120 Capecitabine BYL719 Trastuzumab Lapatinib | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Multicenter Phase II Pilot Open Label | NCT01830504 | Thyroid Cancers | BKM120 | 18 Years - | Hospices Civils de Lyon | |
| Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy | NCT01852292 | Head and Neck S... | Buparlisib Buparlisib matc... Paclitaxel | 18 Years - | Novartis | |
| BKM120 in Cancers With PIK3CA Activating Mutations | NCT01501604 | Lung Cancer Breast Cancer Colorectal Canc... Cholangiocarcin... Solid Tumors | BKM120 | 18 Years - | Massachusetts General Hospital | |
| Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients | NCT01911325 | Squamous Non-sm... | Buparlisib Buparlisib matc... Docetaxel | 18 Years - | Novartis | |
| Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer | NCT02194049 | Extensive Stage... Unspecified Adu... | BKM120 cisplatin etoposide | 18 Years - | University of California, Davis | |
| BKM120 as Second-line Therapy for Advanced Endometrial Cancer | NCT01289041 | Advanced Endome... | BKM120 | 18 Years - | Novartis | |
| Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer | NCT02404844 | Breast Cancer | BKM120 Tamoxifen | 18 Years - | University Hospital, Essen | |
| BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer | NCT01339442 | Estrogen Recept... Recurrent Breas... Stage IV Breast... | BKM120 Fulvestrant biopsy | 18 Years - | Washington University School of Medicine | |
| A Study of BKM120 in Adult Japanese Patients With Advanced Solid Tumors | NCT01283503 | Advanced Solid ... | BKM120 | 20 Years - | Novartis | |
| BKM120 for Patients With PI3K-activated Tumors | NCT01833169 | PI3K Pathway Ac... | BKM120 | 18 Years - 100 Years | Novartis | |
| A Multicenter Phase II Pilot Open Label | NCT01830504 | Thyroid Cancers | BKM120 | 18 Years - | Hospices Civils de Lyon | |
| Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer | NCT01297491 | Non-small Cell ... | BKM120 | 18 Years - | Novartis | |
| A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors | NCT01626209 | Advanced Breast... | BKM120 | 18 Years - | Novartis | |
| A Multicenter Phase II Pilot Open Label | NCT01830504 | Thyroid Cancers | BKM120 | 18 Years - | Hospices Civils de Lyon | |
| BKM120+Abiraterone Acetate for Metastatic CRPC | NCT01741753 | Prostate Cancer | BKM120 Abiraterone Prednisone | 18 Years - | Dana-Farber Cancer Institute | |
| Palliative Thoracic Radiotherapy Plus BKM120 | NCT02128724 | Carcinoma, Non-... | BKM120 | 18 Years - | University of Oxford | |
| Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor | NCT01610284 | Breast Cancer | Fulvestrant BKM120 BKM120 matching... | 18 Years - | Novartis | |
| A Study of BKM120 in Adult Japanese Patients With Advanced Solid Tumors | NCT01283503 | Advanced Solid ... | BKM120 | 20 Years - | Novartis | |
| Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck | NCT02113878 | Carcinoma, Squa... HPV Positive Or... Hypopharyngeal ... Early Invasive ... Carcinoma of La... Cancer of Nasop... | BKM120 Cisplatin Intensity-modul... | 18 Years - | Dana-Farber Cancer Institute | |
| PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer | NCT01248494 | Metastatic Brea... | BEZ235 BKM 120 Letrozole BKM120 | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients | NCT01911325 | Squamous Non-sm... | Buparlisib Buparlisib matc... Docetaxel | 18 Years - | Novartis | |
| A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients | NCT01155453 | Advanced and Se... | BKM120 GSK1120212 | 18 Years - | Novartis | |
| Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer | NCT02194049 | Extensive Stage... Unspecified Adu... | BKM120 cisplatin etoposide | 18 Years - | University of California, Davis | |
| A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab | NCT01285466 | Metastatic or L... | BEZ235 + paclit... BKM120 + paclit... BEZ235 + paclit... BKM120 + paclit... | 18 Years - | Novartis | |
| A Multicenter Phase II Pilot Open Label | NCT01830504 | Thyroid Cancers | BKM120 | 18 Years - | Hospices Civils de Lyon | |
| Neoadjuvant BKM120 in High-risk Prostate Cancer | NCT01695473 | High Risk Prost... | BKM120 | 18 Years - 85 Years | University of California, San Francisco | |
| Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer | NCT01820325 | Non-Small Cell ... | Buparlisib Buparlisib plac... Carboplatin Paclitaxel | 18 Years - | Novartis | |
| P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer. | NCT01591421 | Metastatic Colo... | BKM120 Panitumumab | 18 Years - | Canadian Cancer Trials Group | |
| BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer | NCT01339442 | Estrogen Recept... Recurrent Breas... Stage IV Breast... | BKM120 Fulvestrant biopsy | 18 Years - | Washington University School of Medicine | |
| BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors | NCT01297452 | Solid Tumors | BKM120 days 1 -... BKM120 (days 1 ... BKM120 (days 1-... BKM120, Paclita... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation | NCT01572727 | Breast Cancer | Paclitaxel BKM120 matching... BKM120 | 18 Years - | Novartis | |
| Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients | NCT01634061 | Castration-resi... | BEZ235 BKM120 BEZ235 BKM120 | 18 Years - | Novartis | |
| BKM120 in Cancers With PIK3CA Activating Mutations | NCT01501604 | Lung Cancer Breast Cancer Colorectal Canc... Cholangiocarcin... Solid Tumors | BKM120 | 18 Years - | Massachusetts General Hospital | |
| STAR Cape+BKM120 MBC With Brain Met | NCT02000882 | Brain Metastase... Breast Cancer Metastatic Brea... | BKM120 capecitabine Trastuzumab | 18 Years - | US Oncology Research | |
| A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients | NCT01468688 | 3rd Line GIST | STI571 BKM120 | 18 Years - | Novartis | |
| Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib | NCT01487265 | Non Small Cell ... | BKM120 and Erlo... | 18 Years - | SCRI Development Innovations, LLC | |
| Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer | NCT01300962 | Metastatic Brea... | BMK120 Capecitabine BYL719 Trastuzumab Lapatinib | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Pharmacodynamic Study of BKM120 in Breast Cancer | NCT01513356 | Breast Cancer | BKM120 | 18 Years - | Grupo Hospital de Madrid | |
| BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer | NCT01571024 | Advanced Solid ... Metastatic Colo... Metastatic Panc... | BKM120 mFOLFOX6 | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer | NCT01820325 | Non-Small Cell ... | Buparlisib Buparlisib plac... Carboplatin Paclitaxel | 18 Years - | Novartis | |
| Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer | NCT02088684 | Breast Cancer | LEE011 BYL719 fulvestrant BKM120 | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
